Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy

Cancer

Volumn 119, Issue 1, 2013, Pages 52-60

  Moghanaki, Drew ^a,b   Koontz, Bridget F ^c   Karlin, Jeremy D ^a   Wan, Wen ^d   Mukhopadhay, Nitai ^d   Hagan, Michael P ^a,b,e   Anscher, Mitchell S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

biochemical relapse; elective lymph node; lymph nodes; pelvic lymph nodes; postprostatectomy; prostate cancer; prostatectomy; radiotherapy; salvage radiotherapy; whole pelvis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PELVIS LYMPH NODE; POSTPROSTATECTOMY SALVAGE RADIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BED RADIOTHERAPY; RETROSPECTIVE STUDY; RISK REDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME; WHOLE PELVIS RADIOTHERAPY;

ADULT; AGED; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84872806333     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27712     Document Type: Article

References (19)

1. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294: 433-439.
2. Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007; 25: 2225-2229.
3. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299: 2760-2769.
4. Cotter SE, Chen MH, Moul JW, et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011; 117: 3925-3932.
5. Urdaneta A, Karlin JD, Anscher MS, Moghanaki D,. Current practice trends for managing post-prostatectomy biochemical relapse with salvage radiotherapy: results of a world-wide survey [abstract]. Int J Radiat Oncol Biol Phys. 2011; 81 (suppl): S405.
6. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277: 1445-1451.
7. Ross RW, Zietman AL, Xie W, et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging. 2009; 33: 301-305.
8. Spiotto MT, Hancock SL, King CR,. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007; 69: 54-61.
9. Kim BS, Lashkari A, Vongtama R, Lee SP, Parker RG,. Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer. 2004; 3: 93-97.
10. Rossi CJ Jr, Joe Hsu IC, Abdel-Wahab M, et al. ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancer. Am J Clin Oncol. 2011; 34: 92-98.
11. Bentel GC, Marks LB, Sherouse GW, Spencer DP, Anscher MS,. The effectiveness of immobilization during prostate irradiation. Int J Radiat Oncol Biol Phys. 1995; 31: 143-148.
12. Anscher MS, Robertson CN, Prosnitz R,. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. Int J Radiat Oncol Biol Phys. 1995; 33: 37-43.
13. Wu JJ, King SC, Montana GS, McKinstry CA, Anscher MS,. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys. 1995; 32: 317-323.
14. Bean JM, Montana GS, Clough RW, et al. Standard vs conformal radiation therapy for adenocarcinoma of the prostate: no difference. Prostate Cancer Prostatic Dis. 1998; 1: 216-222.
15. Zhou SM, Bentel GC, Lee CG, Anscher MS,. Differences in gross target volumes on contrast vs noncontrast CT scans utilized for conformal radiation therapy treatment planning for prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998; 42: 73-78.
16. D'Agostino RB Jr,. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17: 2265-2281.
17. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006; 24: 3973-3978.
18. Moghanaki D, Koontz B, Karlin J, et al. Improved biochemical complete response (BCR) and biochemical relapse-free survival (RFS) with whole pelvis (WPRT) vs prostate bed (PBR) radiotherapy in patients undergoing salvage treatment following prostatectomy. Int J Radiat Oncol Biol Phys. 2010; 78 (suppl): S30-231.
19. Deville C, Vapiwala N, Hwang WT, et al. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2011; 82: 1389-1396.